Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
Currently unavailable
This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableNeed the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
GHRP-2 activates GHS-R1a (ghrelin receptor) via phospholipase C / calcium-mediated signaling, producing potent GH release. Unlike ipamorelin, GHRP-2 also significantly stimulates cortisol, prolactin, and ACTH at GH-effective doses — a non-selective GHS-R1a agonism profile useful for full GH secretagogue pharmacology research.
Compound profile
Product definition
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
GHRP-2 (D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide developed as a potent GHS-R1a agonist, and among the first GHRPs characterized in human subjects. Kaken Pharmaceutical's regulatory approval in Japan for GH stimulation testing provides human dose-response and pharmacokinetic data that is available in the published literature — unusual for a GHRP-class compound. The compound's GH-stimulating potency is among the highest of any characterized GHRP hexapeptide. In rodent and human studies, GHRP-2 produces dose-dependent GH release with EC50 in the nanomolar range. However, the same receptor engagement that produces GH release also activates ACTH/cortisol and prolactin secretion at effective GH doses — the pharmacological property that distinguishes it from ipamorelin's selective profile and defines its utility: GHRP-2 is appropriate for full GHS-R1a agonism research; ipamorelin is appropriate for GH-isolated research.
Research audience
GHRP-2 is used by researchers studying GHS-R1a pharmacology, GH secretagogue potency comparison, ACTH/cortisol co-stimulation mechanisms, pituitary hormone co-secretion, and GH axis diagnostic testing paradigms.
Research context
GHRP-2 was characterized in the early 1990s as part of the systematic development of synthetic GH secretagogues following Bowers et al.'s original discovery of the GHRP pharmacological class. Its development into a Japanese-approved GH stimulation test agent represents one of the few examples of a research GHRP reaching regulatory validation — providing a published human pharmacokinetic dataset that anchors its dose-response characterization. In comparative GHRP research, GHRP-2 serves as the 'potent non-selective' reference point against which ipamorelin's selectivity is measured. Studies directly comparing GHRP-2 and ipamorelin in the same animal models documented that ipamorelin produces equivalent or greater GH release with dramatically lower cortisol and prolactin stimulation — establishing ipamorelin's selectivity claim in the published literature. The clinical GH stimulation test use of GHRP-2 (alone and in combination with GHRH) has produced a body of human data on GH reserve assessment that is relevant to researchers studying GH deficiency mechanisms and pituitary somatotrope responsiveness.
Common questions
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableAvailable now
These products from the same research category are currently available for ordering.
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Ipamorelin
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
IGF-1LR3
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
$25.00
$12.00
$30.00
$29.00